Abstract：
OBJECTIVE: We sought to investigate whether the addition of nimotuzumab to gemcitabine would improve the treatment efficacy of advanced pancreatic cancer.
METHODS: This retrospective analysis involved a total of 98 hospitalized patients harboring advanced pancreatic cancer. Depending on the specific treatment, patients were divided into study groups and control groups. The clinical efficacy, adverse reactions, and follow-up results of the 2 groups were compared, and the physical status, CA724, CA19-9, and CEA levels before and after treatment were monitored and recorded.
RESULTS: After treatment, PR ratio, SD ratio, ORR, and DCR in the study group were significantly higher than those in the control group, and PD ratio was significantly lower than that in the control group (P < 0.05) the KPS score after treatment in the study group was markedly higher than that of the control group (P < 0.05). After treatment, however, significantly lower levels of the 3 indicators were observed when compared with the control group (P < 0.05).
CONCLUSIONS: Our study highlights a more superior combined efficacy of nimotuzumab and gemcitabine than the control regimen, exhibiting improved survival and reduced levels of CA724, CA19-9, and CEA in patients with advanced pancreatic cancer.
METHODS: This retrospective analysis involved a total of 98 hospitalized patients harboring advanced pancreatic cancer. Depending on the specific treatment, patients were divided into study groups and control groups. The clinical efficacy, adverse reactions, and follow-up results of the 2 groups were compared, and the physical status, CA724, CA19-9, and CEA levels before and after treatment were monitored and recorded.
RESULTS: After treatment, PR ratio, SD ratio, ORR, and DCR in the study group were significantly higher than those in the control group, and PD ratio was significantly lower than that in the control group (P < 0.05) the KPS score after treatment in the study group was markedly higher than that of the control group (P < 0.05). After treatment, however, significantly lower levels of the 3 indicators were observed when compared with the control group (P < 0.05).
CONCLUSIONS: Our study highlights a more superior combined efficacy of nimotuzumab and gemcitabine than the control regimen, exhibiting improved survival and reduced levels of CA724, CA19-9, and CEA in patients with advanced pancreatic cancer.
摘要：
目的：我们试图研究在吉西他滨基础上加用尼妥珠单抗是否能提高晚期胰腺癌的疗效。
方法：本回顾性分析共纳入98例晚期胰腺癌住院患者。根据具体的治疗方法,将患者分为研究组和对照组。临床疗效,不良反应,并对2组的随访结果进行比较,和身体状况，监测并记录治疗前后的CA724、CA19-9和CEA水平。
结果：治疗后，PR比率，SD比率,ORR,研究组DCR明显高于对照组,治疗后研究组KPS评分明显高于对照组(P<0.05)。治疗后,然而,3项指标均显著低于对照组(P<0.05)。
结论：我们的研究强调尼妥珠单抗和吉西他滨的联合疗效优于对照方案，晚期胰腺癌患者的生存率提高，CA724，CA19-9和CEA水平降低。
方法：本回顾性分析共纳入98例晚期胰腺癌住院患者。根据具体的治疗方法,将患者分为研究组和对照组。临床疗效,不良反应,并对2组的随访结果进行比较,和身体状况，监测并记录治疗前后的CA724、CA19-9和CEA水平。
结果：治疗后，PR比率，SD比率,ORR,研究组DCR明显高于对照组,治疗后研究组KPS评分明显高于对照组(P<0.05)。治疗后,然而,3项指标均显著低于对照组(P<0.05)。
结论：我们的研究强调尼妥珠单抗和吉西他滨的联合疗效优于对照方案，晚期胰腺癌患者的生存率提高，CA724，CA19-9和CEA水平降低。
